EMA Committee Backs Approval of Sacubitril/Valsartan (Entresto)EMA Committee Backs Approval of Sacubitril/Valsartan (Entresto)

The recommendation is for heart-failure patients with reduced ejection fraction. However, the organization notes it shouldn't be started in those with low blood pressure or high potassium levels. International Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news